Remedium with reference to FierceBiotech informs that on the findings of the clinical research studies, the new trial three-in-one inhaler from AstraZeneca has outperformed in terms of efficiency Symbicort and other two-drug inhalers.
Farmak JSC and Ukrainian football association of medical doctors (UFAM) have signed the Memorandum on cooperation for 2018 in order to consolidate partnerships relations in organization of sport events.
International festival-contest "Choice of the Year" is one of the most famous and authoritative ratings in Ukraine. This year, for the 17th time, the most popular trademarks of our country were announced. More than 2000 nominees competed in different categories for being recognized.
Detailed plan for reorganization will be unveiled shortly and five new TOP-managements are to come into TEVA governance.
Kare Shultz, New Chief Executive Officer of Israel–based pharmaceutical company TEVA has made a decision to fire several TOP-managers of the Company
Sandoz arranged live broadcast of the international webinar in an effort to increase awareness of the medical community as to antibiotic therapies.
Sandoz arranged web broadcast of the scientific event designed at increasing the access to information on proper antibiotics therapies for the HCPs (Healthcare professionals).
The outstanding research and practice conference with international participation “Gynecological disorders. Is there the unclosed window of opportunities?" was held in Kiev in November 2017.
TV advertising in the pharmaceutical industry is very popular. During the six months of 2017, the advertising budget exceeded $ 1.75 billion, compared with $ 1.5 billion last year.
The world's leading pharmaceutical company “AstraZeneca” shared the news the FDA called its product "breakthrough" again. This product is the second drug acquired such a status in a short time. The first drug “Imfinzi” has been developed for the treatment of lung cancer, the second one - for the treatment of blood cancer (“Acalabrutinib”).
The rating of 50 largest pharmaceutical companies was published in the “Pharmaceutical Executive” according to the results of 2016. The companies were estimated by the volume of sales of prescription drugs and by the investments in scientific development (R & D).